Biotinylated mAb cocktail effective for isolating Low Density Granulocytes from SLE patient blood

Featured product: Ancell Biotinylated mAb cocktail effective for Negative selection of Low Density Granulocyte(LDG) population from Systemic Lupus Erythematosis (SLE) patient blood. “A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs “ M.F. Denny, M.J. Kaplan, et al.  (2010) J Immunol  184(6): 3284-3297 […]

Biotinylated mAb cocktail effective for isolating Low Density Granulocytes from SLE patient blood Read More »

CD64 FcγRI, CD32FcγRII, CD16FcγRIII F(ab’)2

Featured Products: F(ab’)2 Fragments of anti-CD64(FcgRI), anti-CD32(FcgRII), and anti-CD16(FcgRIII) for Human Fc Receptor and Immune Complex  Research Low Endotoxin and Essentially Free of Intact Antibody, these dimericantibody fragments block Immunoglobulin binding to their repective receptors anti-human CD64 (FcgRI)F(ab’)2 clone 10.1 anti-human CD32 (FcgRII) F(ab’)2 clone 7.3 anti-human CD16 (FcgRIII) F(ab’)2 clone 3G8 Literature Citations Inhibition

CD64 FcγRI, CD32FcγRII, CD16FcγRIII F(ab’)2 Read More »

Cell Surface Metastatic Markers for Colon Cancer SW480/SW620 Model

SW480 is a primary Colon Epithelial Adenocarcinoma tumor line and SW620 is a metastasized variant of this derived from lymph node.  Differential analysis of surface markers may give insight into tumor metastatic potential and/or mechanisms.   “Multiplex Flow Cytometry Barcoding and Antibody Arrays Identify Surface Antigen Profiles of Primary and Metastatic Colon Cancer Cell Lines”

Cell Surface Metastatic Markers for Colon Cancer SW480/SW620 Model Read More »

Clinical Response to Prostate Cancer Immunotherapy using GM-CSF and anti-CD152 Correlates with Diversity of Upmodulated Antibody Binding to Microarray Antigens

“Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients”   Kwek S S, L Fong, et al. (Oct 2012)  J Immunol 189(7): 3759-3766.  “…advanced prostate cancer patients who clinically respond to treatment also develop enhanced Ab responses to a higher number of Ags than nonresponders…” Relevant Ancell Products Anti-CD152(CTLA-4) blocking mAb

Clinical Response to Prostate Cancer Immunotherapy using GM-CSF and anti-CD152 Correlates with Diversity of Upmodulated Antibody Binding to Microarray Antigens Read More »

CD49d is a useful marker for sorting FoxP3+ human Treg

”CD49d provides access to “untouched” human Foxp3 Treg free of contaminating effector cells” Kleinewietfeld M, K Falk, et al. (2012) Blood 113(4): 827-836.   Magnetic depletion of PBMC using anti-CD127 (Clone hIL7R-M21) and anti-CD49d (Clone BU49) mAbs to yield a pure population of Foxp3 + Treg cells!   Relevant Ancell products:  anti-CD49d (clone BU49) anti-CD127

CD49d is a useful marker for sorting FoxP3+ human Treg Read More »